Comparative Pharmacology
Head-to-head clinical analysis: DECLOMYCIN versus VIBRA TABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECLOMYCIN versus VIBRA TABS.
DECLOMYCIN vs VIBRA-TABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
100 mg orally twice daily on day 1, then 100 mg orally once daily
None Documented
None Documented
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Terminal elimination half-life: 18-22 hours (single dose); increases to 24-48 hours in renal impairment. Mean half-life after multiple doses: 14-16 hours.
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Renal (40% as unchanged drug via glomerular filtration), biliary/fecal (20-30%, including enterohepatic circulation).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic